Tadekinig alfa

DB14858Investigational

Tadekinig alfa is under investigation in clinical trial NCT03113760 (Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency).

Mechanism
Curator reviewed

Resolves to

Compound
UNII3G6834I4PFCAS220712-29-8
Targets
Q14116IL18

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
3Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with Tadekinig alfa, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In